KeiS a medical professional

This is a blog about the scientific basis of medicine. A judo therapist reads research papers for study and writes about them.

sponsorlink

HOME/Vaccines/

Effectiveness of the UK HPV vaccination programme.

Thursday, November 4, 2021

Vaccines

Effect of the UK and UK national HPV vaccination programme on the incidence of cervical cancer and grade 3 cervical intraepithelial tumours: a registry-based observational study

Publication date: November 3, 2021 DOI: https : //doi.org/10.1016/S0140-6736(21)02178-4

Commentary

Human papillomavirus (HPV) immunization with a bivalent vaccine (Cervarix) was introduced in England on September 1, 2008, and routine immunization was offered to girls aged 12-13 years through a catch-up program for women aged 14-18 years.

We quantified the initial impact of this immunization program on the registration of cervical and intraepithelial cancers and grade 3 cervical intraepithelial tumors (CIN3).　In this observational study, we used an extension of the Poisson model of cohorts to estimate the relative risk of cervical cancer in three vaccinated cohorts compared with a previous cohort that was not eligible for HPV vaccination.

Data from population-based cancer registries were extracted on 26 January 2021 and assessed for diagnoses of cervical cancer and CIN3 in UK resident women aged 20-64 years from 1 January 2006 to 30 June 2019.

Three vaccination cohorts were used to account for differences in the year in which the vaccine was offered and its national coverage. Using data from a total of 13 million years of follow-up of women between the ages of 20 and 30, the estimated relative reduction in cervical cancer incidence by age at the time of vaccine provision was 34% (95% CI 25-41) for 16-18 year olds (grades 12-13) and 62% (52-71) for 14-16 year olds. Compared to the unvaccinated reference cohort, it was shown to be 87% in 12-13 year olds (grades 8). (72-94)

The corresponding risk reduction for CIN3 was 39% (95% CI 36-41) for those offered at 16-18 years, 75% (72-77) at 14-16 years, and 97% (96-98) at

After the introduction of the HPV immunization program in the UK, a significant reduction in the incidence of cervical cancer and CIN3 in young women was observed, especially in individuals offered the vaccine at the age of 12-13 years.

QooQ